Correspondence 0001178913-24-003302 from Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp
Date: Oct. 15, 2024 · CIK: 0002022416 · Accession: 0001178913-24-003302
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282556
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences100 F Street, NE Attention: Tamika Sheppard Re: Silexion Therapeutics Corp Registration Statement on Form S-1 SEC File Number 333-282556
Dear Ms. Sheppard:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will become effective at 9:00 a.m. Eastern time on October 16, 2024, or as soon as practicable thereafter.
Please contact Gary Emmanuel, Esq., at Greenberg Traurig, LLP, our U.S. legal counsel, at +972-3-636-6033 or Gary.Emmanuel@gtlaw.com, or Jonathan M. Nathan, Adv., at Meitar Law Offices, our Israeli legal counsel, at +972-52-312-5574 or jonathann@meitar.com, with any questions, and please notify them when this request for acceleration has been granted.
Sincerely,
/s/ Ilan Hadar
Show Raw Text
CORRESP
1
filename1.htm
Silexion Therapeutics Corp
12 Abba Hillel Road
Ramat Gan, Israel 5250606
Telephone: +972-8-6286005
October 15, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences100 F Street, NE
Washington, DC 20549
Attention: Tamika Sheppard
Re:
Silexion Therapeutics Corp
Registration Statement on Form S-1
SEC File Number 333-282556
Dear Ms. Sheppard:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will become effective at 9:00 a.m. Eastern time on October
16, 2024, or as soon as practicable thereafter.
Please contact Gary Emmanuel, Esq., at Greenberg Traurig, LLP, our U.S. legal counsel, at +972-3-636-6033 or
Gary.Emmanuel@gtlaw.com, or Jonathan M. Nathan, Adv., at Meitar Law Offices, our Israeli legal counsel, at +972-52-312-5574 or jonathann@meitar.com, with any questions, and please notify them when this request for acceleration has been granted.
Sincerely,
/s/ Ilan Hadar
Ilan Hadar
Chief Executive Officer
CC:
Mirit Horenshtein Hadar
Silexion Therapeutics Corp
Mark S. Selinger, Esq.
Gary Emmanuel, Esq.
Greenberg Traurig, LLP
J. David Chertok, Adv.
Jonathan M. Nathan, Adv.
Meitar Law Offices